Sharing of experience amongst transplant community through various platforms and rapid publications has proven invaluable during the COVID‐19 pandemic (1‐3). The general consensus seemed to be that most kidney transplant recipients would have a moderate or mild course, although some may progress to a more severe disease. It was recommended to stop or decrease the dose of anti‐proliferative agents and continue with calcineurin inhibitors (CNIs) and maintenance steroids (4).